Back to Search
Start Over
Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
- Source :
- Clinical Lymphoma, Myeloma & Leukemia; 2019 Supplement 1, Vol. 19, pS221-S222, 2p
- Publication Year :
- 2019
Details
- Language :
- English
- ISSN :
- 21522650
- Volume :
- 19
- Database :
- Complementary Index
- Journal :
- Clinical Lymphoma, Myeloma & Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 142669381
- Full Text :
- https://doi.org/10.1016/j.clml.2019.07.097